 Hikma Pharmaceuticals OTCMKTS:HKMPF was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Wednesday, Zacks.com reports. The brokerage currently has a 32.00 price objective on the stock. Zacks Investment Researchs price objective suggests a potential upside of 13.07 from the companys current price. According to ... 